What is MOUNJARO® 7.5mg KwikPen®
MOUNJARO® 7.5mg KwikPen® is a pre-filled, disposable injection pen that provides a 7.5 mg tirzepatide dose in 0.6 mL weekly. It is used for adults with type 2 diabetes requiring additional glycaemic control and for weight management in adults meeting BMI criteria. Each pen contains 30 mg tirzepatide in 2.4 mL solution, sufficient for four weekly injections. The solution is clear, colourless to slightly yellow, administered subcutaneously in the abdomen, thigh, or upper arm.
- Per dose: 7.5 mg tirzepatide (0.6 mL)
- Total pen content: 30 mg/2.4 mL (12.5 mg/mL)
- Doses per pen: 4
- Route: Subcutaneous
- Injection areas: Abdomen, thigh, upper arm
What is the Administration Protocol for MOUNJARO® 7.5mg KwikPen®
The 7.5 mg strength is commonly prescribed as a titration step. The regimen follows a structured weekly schedule.
- Initial regimen: Begin at 2.5 mg for 4 weeks, then escalate
- Titration: 7.5 mg is an intermediate step toward higher doses
- Maintenance: Doses can be 5 mg, 10 mg, or 15 mg weekly as indicated
- Missed dose protocol:
- ≤4 days late: administer promptly
- 4 days late: skip dose and continue schedule
- Administration steps:
- Always use a new sterile needle
- Dial to 1 (=0.6 mL)
- Inject subcutaneously, hold for 5 seconds until window shows 0
- Site rotation: Required to reduce injection-site discomfort
What are the Indications for MOUNJARO® 7.5mg KwikPen®
This dose is indicated for adults with metabolic conditions requiring stepwise therapy.
- Indications:
- Adults with type 2 diabetes inadequately controlled with current regimen
- Adults with BMI ≥30 kg/m² (obesity)
- Adults with BMI ≥27 to <30 kg/m² plus weight-related comorbidities
- Contraindications:
- Hypersensitivity to tirzepatide or excipients
- Precautions:
- History of pancreatitis
- Severe gastrointestinal conditions
- Adverse effects:
- Common: nausea, diarrhoea, vomiting, abdominal pain, constipation
- Hypoglycaemia risk with sulphonylureas or insulin
- Injection-site reactions up to 6%
- Gallbladder disorders in 1–2%
- Rare: acute pancreatitis, hypersensitivity
What is the composition of MOUNJARO® 7.5mg KwikPen®
The formulation contains tirzepatide and excipients ensuring safety and usability.
- Active substance: Tirzepatide 7.5 mg/0.6 mL
- Total pen content: 30 mg/2.4 mL
- Concentration: 12.5 mg/mL
- Excipients: Benzyl alcohol (~5.4 mg/dose), disodium hydrogen phosphate heptahydrate, glycerol, phenol, sodium chloride, sodium hydroxide, hydrochloric acid, water for injections
- Sodium level: <1 mmol sodium (sodium-free)
- Appearance: Clear, colourless to slightly yellow
What Comes in the MOUNJARO® 7.5mg KwikPen® Package
The packaging provides the pen and informational leaflets.
- Presentation: Pre-filled KwikPen® with 2.4 mL (4 doses)
- Pack sizes: 1 or 3 pens per carton
- Needles: Not included in packaging
- Documentation: Instructions for Use and Patient Leaflet
Does MOUNJARO® 7.5mg KwikPen® cause side effects?
Side effects are most frequently gastrointestinal, particularly during titration.
- Very common: Nausea, diarrhoea, vomiting, constipation, abdominal pain
- Hypoglycaemia: Increased risk with insulin or sulphonylurea combinations
- Injection-site reactions: Mild, up to 6% of patients
- Gallbladder events: Occur in 1–2%
- Rare but serious: Acute pancreatitis, allergic reactions
- Laboratory values: Elevations in amylase and lipase
How should MOUNJARO® 7.5mg KwikPen® be stored?
Correct storage preserves product integrity.
- Unopened pens: Refrigerate at 2–8 °C
- Do not freeze; discard if frozen
- In-use pens: Store at ≤30 °C for a maximum of 30 days
- Discard after 30 days, regardless of remaining liquid
- Needles: Remove after each injection, discard in sharps container
- Keep away from children